摘要
本文从经济学角度,对中国的反垄断并购审查进行梳理,着重从竞争分析和救济措施两个方面与国际主流反垄断执法原则进行比较。综观商务部所公布的予以干预的决定公告,商务部反垄断局的竞争分析框架与主流反垄断执法做法基本一致,注重竞争分析,但对于并购产生的效率尚缺乏明确的讨论。在救济措施方面,就目前公告的案件而言,商务部更多的采用了行为性救济,而且某些救济措施对企业的运营深度介入,这与其他国家竞争执法机构的做法有所不同。
This article summarizes China's merger review focusing on the competitive analysis and merger remedies from an economic perspective. It compares and contrasts China's experiences with those from the international antitrust community. Based on the published decisions in the transactions in which the Ministry of Commerce(MOFCOM) intervened, China's merger review is largely consistent with mainstream antitrust approaches typically incorporating the key elements of competitive analysis. To date, MOFCOM has not explicitly addressed any merger-generated effi ciency in its decisions. When a merger is determined to have anticompetitive effects, thus far, behavioral remedies in China are used more often, with extensive and detailed requirements on certain transactions. This is a key difference between China and the practices in other major antitrust jurisdictions regarding merger remedies.
出处
《竞争政策研究》
2015年第1期97-104,共8页
Competition Policy Research
关键词
并购审查
竞争分析
救济措施
merger review
competitive analysis
merger remedies
